Enzon Pharmaceuticals (ENZN)
Enzon Pharmaceuticals
NASDAQ:ENZN (5/19/2016, 7:47:32 PM)
After market: 0.46 0 (0%)0.46
+0.01 (+2.22%)
Company Profile
Enzon Pharmaceuticals, Inc. is a biotechnology company. It discovers, develops, and commercializes therapeutics to treat life-threatening diseases. The Company's marketed drug products include PegIntron (R) for chronic hepatitis C; Sylatron (R) for Melanoma; Macugen (R) for neovascular age-related macular degeneration; CIMZIA (R) for Crohn's disease; Oncaspar for acute lymphoblastic leukemia; and Adagen for severe combined immunedeficiency. Enzon Pharmaceuticals, Inc. is headquartered in Piscataway, New Jersey.
Company Info
Enzon Pharmaceuticals
20 Commerce Drive Suite 135
Cranford NJ 07016
P: 732-980-4500
CEO: Andrew Rackear
ENZN News
3 years ago - Enzon Pharmaceuticals, IncEnzon Pharmaceuticals, Inc. CEO Andrew Rackear to Retire; Richard L. Feinstein, Enzon’s CFO, to Assume Position of CEO and Remain CFO4 years ago - Enzon Pharmaceuticals, IncEnzon Pharmaceuticals Announces Results of Rights OfferingLooking to Next Step – Acquisition Opportunities
4 years ago - Enzon Pharmaceuticals, IncEnzon Pharmaceuticals Announces Key Dates for Rights Offering
4 years ago - BusinessInsiderEnzon Pharmaceuticals, Inc. Announces Postponement of 2020 Annual MeetingCRANFORD, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its 20...
4 years ago - Enzon Pharmaceuticals, IncEnzon Pharmaceuticals, Inc. Announces Postponement of 2020 Annual Meeting
4 years ago - Seeking AlphaEnzon Pharmaceuticals' board approves rights offering (OTCMKTS:ENZN)Under the board approved rights offering to existing shareholders, Enzon Pharmaceuticals' (OTC:ENZN) seeks to distribute one transferable subscription right for each outstanding share of common stock owned.For every 1,105 subscription rights held, a shareholder will be entitled to purchase one unit.Enzon plans to offer 40K units at a subscription price of $1,090/unit; each unit will consist of one preferred share par value $1,000, and 750 common stock shares.With no voting rights, preferred stock holders will be entitled to receive cumulative dividends at the rate per share of 3% p.a., if paid in cash, or 5% p.a., if paid in-kind.
ENZN Twits
Here you can normally see the latest stock twits on ENZN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
